{
    "nct_id": "NCT03248492",
    "official_title": "A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1 (DESTINY-Breast01)",
    "inclusion_criteria": "* Men or women the age of majority in their country\n* Has pathologically documented breast cancer that:\n\n  1. is unresectable or metastatic\n  2. has HER2 positive expression confirmed per protocol\n* Has an adequate tumor sample\n* Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n* Has protocol-defined adequate cardiac, renal and hepatic function\n* Agrees to follow protocol-defined method(s) of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia\n* Has a corrected QT interval (QTc) prolongation to > 450 millisecond (ms) in males and > 470 ms in females\n* Has a medical history of clinically significant lung disease\n* Is suspected to have certain other protocol-defined diseases based on imaging at screening period\n* Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:\n\n  1. safety or well-being of the participant or offspring\n  2. safety of study staff\n  3. analysis of results",
    "miscellaneous_criteria": ""
}